Olanzapine is indicated for the treatment of schizophrenia.
In patients who initially responded to treatment, olanzapine has demonstrated its effectiveness in maintaining this clinical improvement over the long term.
Olanzapine is also indicated for the treatment of moderate to severe manic episodes and for the prevention of relapses in patients with bipolar disorder who have previously responded to olanzapine treatment during a manic episode.
| Specialty | OLANZA ODT |
|---|---|
| Dosage | 5 mg |
| Form | Orodispersible tablet |
| Presentation | BOX OF 30 |
| Primary Packaging | Blister |
| Specification | ALU, PA, PVC |
| Active Ingredient (DCI) | OLANZAPINE |
| VEIC Classification | Essential |
| Therapeutic Class | Nervous System |
| Sub Class | Psycholeptics |
| Laboratory | PHILADELPHIA PHARMA |
| Table | A |
| Shelf Life | 2 years |
| Generic/Brand | Generic |
| Marketing Authorization (AMM) | 9353311 |
| AMM Date | 26/03/2026 |
| Range | NeuroPsy |
You must be logged in to post a review.
Reviews
There are no reviews yet.